6-K - MCUJF - Equibles

UNITED STATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM 6-K

REPORT OFFOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THESECURITIES EXCHANGE ACT OF 1934

For the month of September 2020

Commission File Number: 001-31995

MEDICUREINC.

(Translation of registrant's name into English)

2-1250 Waverley Street

Winnipeg, MB Canada R3T 6C6

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.

EXHIBITLIST

Exhibit	Title
99.1	Material Change Report dated September 1, 2020
99.2	Material Change Report dated September 1, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Medicure Inc.
	(Registrant)
Date: September 1, 2020	By:	/s/ Dr. Albert D. Friesen
		Dr. Albert D. Friesen
		Title: CEO

Exhibit 99.1

MATERIAL CHANGE REPORT

PURSUANT TO SECTION 7.1 OF NATIONAL INSTRUMENT51-102

1.	Name and Address of Company:

Medicure Inc. (“Medicure” or the “Corporation”)

2 – 1250 Waverley Street

Winnipeg, Manitoba R3T 6C6

2.	Date of Material Change:

August 20, 2020

3.	News Release:

A press release with respect to the material change described herein was issued on August 20, 2020 and filed on SEDAR.

4.	Summary of Material Change:

Medicure announced the termination of the marketing and distribution agreement with Sensible Medical Innovations Inc. (“Sensible”) for the marketing of the ReDS^TM^Pro (“ReDS Pro”) device in the United States. In connection with the termination, Sensible and the Company have entered into a transition agreement which provides additional compensation to Medicure for sales to customer leads provided by Medicure.

5.	Full Description Of Material Change:

See Attached Schedule “A”.

6.	Reliance on subsection 7.1(2) of National Instrument 51-102:

Not Applicable.

7.	Omitted Information:

Not Applicable.

8.	Executive Officer:

For further information contact James Kinley, Chief Financial Officer of Medicure Inc. (204) 487-7412.

Dated at Winnipeg, Manitoba this 1^st^ day of September 2020

MEDICURE INC.

Per: “James Kinley”

Chief Financial Officer

SCHEDULE “A”

MEDICURE ANNOUNCES TERMINATION OF REDS^TM^PRO MARKETING AND DISTRIBUTION AGREEMENT

STRENGTHENS FOCUS ON MARKETING OF AGGRASTAT^®^AND ZYPITAMAG^TM^

WINNIPEG, CANADA – (August 20, 2020) Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today announced the termination of the marketing and distribution agreement with Sensible Medical Innovations Inc. (“Sensible”) for the marketing of the ReDS^TM^Pro (“ReDS Pro”) device in the United States. In connection with the termination, Sensible and the Company have entered into a transition agreement which provides additional compensation to Medicure for sales to customer leads provided by Medicure.

Medicure continues to hold a 7.71% equity stake, on a fully diluted basis, in Sensible Medical Innovations Ltd. (“Sensible Medical”), the parent company of Sensible. Medicure will continue to support Sensible in its transition to a new marketing and distribution arrangement in order to secure its investment in Sensible Medical.

The termination of the marketing and distribution agreement with Sensible followed an in-depth strategic review of its alignment with Medicure’s other lines of business. “The discontinuation of marketing and distribution activities related to the ReDS Pro device in the United States market will result in Medicure strengthening its focus on its own products, AGGRASTAT^®^ and ZYPITAMAG^TM^, which provide a higher profit margin to Medicure” commented Dr. Albert D. Friesen, Medicure’s Chief Executive Officer.

About Medicure Inc.

Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT^®^ (tirofiban hydrochloride) injection and ZYPITAMAG^TM^ (pitavastatin) tablets in the United States, where they are sold through the Company’s U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit www.medicure.com.

About Sensible

Sensible is a market leader in medical radar monitoring and imaging technology. ReDS™ was adapted for medical use from military 'see-through-wall' technology. The technology is well-positioned to be a difference maker in a wide range of applications and to become the next-generation lung fluid monitoring modality. www.sensible-medical.com

About ReDS™PRO System

The ReDS™ PRO is an accurate measurement tool to evaluate pulmonary congestion providing additional information to assist a physician in their assessment of a patient's condition. Assessment with the aid of ReDS™ technology has helped physicians at facilities across the country to better manage their patients' heart failure, with the goal of avoiding readmissions. For more information please visit www.medicure.com/reds.

For more information, please contact:

James Kinley

Chief Financial Officer

Tel. 888-435-2220

Fax 204-488-9823

E-mail: info@medicure.com

www.medicure.com ****

To be added to Medicure’s e-mail list,please visit: http://medicure.mediaroom.com/alerts

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy oraccuracy of this release.

Forward Looking Information: Statementscontained in this press release that are not statements of historical fact, including, without limitation, statements containingthe words "believes", "may", "plans", "will", "estimates", "continues","anticipates", "intends", "expects" and similar expressions, may constitute "forward-lookinginformation" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking informationand forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-lookingstatements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perceptionof trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant andreasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factorsbeyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially differentfrom any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers arecautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's futureproduct revenues, expected future growth in revenues, stage of development, additional capital requirements, risks associated withthe completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability toprotect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approvalprocesses, and rapid technological change in the industry. Such statements are based on a number of assumptions which may proveto be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changesin Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receiptof regulatory and governmental approvals for the Company's research and development projects; the availability of financing forthe Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms;results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products andmarket competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligationto update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be requiredby applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its businesscan be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securitiesand Exchange Commission, and in the "Risk Factors" section of its Form 20F for the year ended December 31, 2019.

Exhibit 99.2

MATERIAL CHANGE REPORT

PURSUANT TO SECTION 7.1 OF NATIONAL INSTRUMENT51-102

1.	Name and Address of Company:

Medicure Inc. (“Medicure” or the “Corporation”)

2 – 1250 Waverley Street

Winnipeg, Manitoba R3T 6C6

2.	Date of Material Change:

August 24, 2020

3.	News Release:

A press release with respect to the material change described herein was issued on August 24, 2020 and filed on SEDAR.

4.	Summary of Material Change:

Medicure announced that early investigator sponsored clinical reports evaluating the efficacy of AGGRASTAT^®^ (tirofiban hydrochloride) show promise for preventing and treating thrombotic complications due to COVID-19. AGGRASTAT^®^ is not currently indicated for use in patients with COVID-19.

5.	Full Description Of Material Change:

See Attached Schedule “A”.

6.	Reliance on subsection 7.1(2) of National Instrument 51-102:

Not Applicable.

7.	Omitted Information:

Not Applicable.

8.	Executive Officer:

For further information contact James Kinley, Chief Financial Officer of Medicure Inc. (204) 487-7412.

Dated at Winnipeg, Manitoba this 1^st^ day of September 2020

MEDICURE INC.

Per: “James Kinley”

Chief Financial Officer

SCHEDULE “A”

MEDICURE ANNOUNCES AGGRASTAT^®^SHOWS PROMISE IN TREATING THROMBOTIC COMPLICATIONS DUE TO COVID-19 IN EARLY CLINICAL REPORTS

WINNIPEG, CANADA – (August 24, 2020) Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is reporting that early investigator sponsored clinical reports evaluating the efficacy of AGGRASTAT^®^ (tirofiban hydrochloride) show promise for preventing and treating thrombotic complications due to COVID-19. AGGRASTAT^®^ is not currently indicated for use in patients with COVID-19.

Notably, a non-randomized, case-controlled, investigator sponsored proof of concept study (n=10) evaluating AGGRASTAT^®^ in combination with standard of care in patients with severe COVID-19 and hypercoagulability found that enhanced platelet inhibition improves hypoxemia (https://clinicaltrials.gov/ct2/show/NCT04368377). Treated patients experienced a mean reduction in alveolar-arterial oxygen gradient and an increase in PaO2/FiO2 (ratio of partial arterial pressure of oxygen to fraction of inspired oxygen) at 24h, 48h and 7 days after treatment. Seven other small clinical reports have recently been published exploring the clinical efficacy of AGGRASTAT^®^ in patients with COVID-19.

Medicure is evaluating sponsorship of further US-based randomized clinical studies to rapidly assess the efficacy and safety of using AGGRASTAT^®^ for preventing thrombotic complications due to COVID-19.

“These initial results are sufficiently positive to warrant further investigation to more clearly understand the potential role of AGGRASTAT^®^ to reduce thrombotic effects which are observed in many COVID-19 patients”, commented Medicure’s CEO, Dr. Albert D. Friesen. “We believe there is reason to sponsor this type of clinical research due to the emerging understanding of the role of thrombosis in the pathophysiology of COVID-19.”

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time. A list of the reports referred to can be provided upon request.

About AGGRASTAT^®^

AGGRASTAT^®^ is not indicated for use in patients with COVID-19, nor has the safety or efficacy been established in this patient population. AGGRASTAT^®^ is an IV antiplatelet medication indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). AGGRASTAT^®^ is currently the most widely used GP IIb/IIIa inhibitor in the U.S. and has several administration benefits including room temperature storage, a 3-year shelf life and is available in pre-mixed formats. Please refer to the IMPORTANT SAFETY INFORMATION below.

About Medicure Inc.

Important Safety Information for AGGRASTAT®(tirofiban hydrochloride)

Indications and Usage

AGGRASTAT^®^ is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Dosage and Administration

Administer intravenously 25 mcg/kg within 5 minutes and then 0.15 mcg/kg/min for up to 18 hours. In patients with creatinine clearance ≤60 mL/min, give 25 mcg/kg within 5 minutes and then 0.075 mcg/kg/min.

Contraindications

Known hypersensitivity to any component of AGGRASTAT^®^, history of thrombocytopenia with prior exposure to AGGRASTAT^®^, active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within previous month.

Warnings and Precautions

AGGRASTAT^®^ can cause serious bleeding. Most bleeding associated with AGGRASTAT^®^ occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. If bleeding cannot be controlled, discontinue AGGRASTAT^®^.

Thrombocytopenia: Discontinue AGGRASTAT^®^ and heparin.

Adverse Reactions

Bleeding is the most commonly reported adverse reaction.

For more information on AGGRASTAT^®^, please refer to Full Prescribing Information available at www.aggrastatHDB.com.

To be added to Medicure’s e-mail list,please visit: http://medicure.mediaroom.com/alerts

Forward Looking Information: Statementscontained in this press release that are not statements of historical fact, including, without limitation, statements containingthe words "believes", "may", "plans", "will", "estimates", "continues","anticipates", "intends", "expects" and similar expressions, may constitute "forward-lookinginformation" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking informationand forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-lookingstatements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perceptionof trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant andreasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factorsbeyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially differentfrom any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers arecautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's futureproduct revenues, the ability of AGGRASTAT^®^ to provide benefits to COVID-19 patients, expected future growthin revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinicaltrials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependenceupon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological changein the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limitedto, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreignexchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvalsfor the Company's research and development projects; the availability of financing for the Company's commercial operations and/orresearch and development projects, or the availability of financing on reasonable terms; results of current and future clinicaltrials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing listof important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise reviseany forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additionaldiscussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filingswith the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "RiskFactors" section of its Form 20F for the year ended December 31, 2019.

For more information, please contact:

James Kinley

Chief Financial Officer

Tel. 888-435-2220

Fax 204-488-9823

E-mail: info@medicure.com